Over the last 7 days, the United States market has risen by 1.8%, and over the past 12 months, it is up by 14%, with earnings forecasted to grow by 15% annually. In this favorable environment, stocks with high insider ownership often stand out as they suggest strong confidence from those closest to the company's operations, making them attractive options for investors seeking growth opportunities.
Top 10 Growth Companies With High Insider Ownership In The United States
| Name | Insider Ownership | Earnings Growth |
| XPeng (XPEV) | 20.7% | 66.3% |
| Wallbox (WBX) | 15.4% | 75.8% |
| Super Micro Computer (SMCI) | 13.9% | 39.1% |
| Prairie Operating (PROP) | 34.6% | 92.4% |
| Pagaya Technologies (PGY) | 16.1% | 119.4% |
| FTC Solar (FTCI) | 28.3% | 62.5% |
| Enovix (ENVX) | 12.1% | 58.4% |
| Credo Technology Group Holding (CRDO) | 11.8% | 47% |
| Atour Lifestyle Holdings (ATAT) | 21.8% | 23.7% |
| Astera Labs (ALAB) | 13.1% | 44.4% |
Let's review some notable picks from our screened stocks.
IREN (IREN)
Simply Wall St Growth Rating: ★★★★★☆
Overview: IREN Limited owns and operates bitcoin mining data centers, with a market cap of $4.07 billion.
Operations: The company generates revenue of $377.82 million from building and operating data center sites dedicated to bitcoin mining.
Insider Ownership: 13%
Earnings Growth Forecast: 115.7% p.a.
IREN is poised for significant growth with forecasted revenue increase of 43.4% annually, surpassing the US market average. Despite past shareholder dilution and a low cash runway, its profitability is expected to rise over 115.69% per year in the next three years. The recent appointment of Anthony Lewis as Chief Capital Officer aims to enhance capital strategy amidst AI infrastructure investments, while substantial shelf registrations indicate potential capital raising efforts totaling US$252.17 million this year.
- Unlock comprehensive insights into our analysis of IREN stock in this growth report.
- The valuation report we've compiled suggests that IREN's current price could be quite moderate.
Krystal Biotech (KRYS)
Simply Wall St Growth Rating: ★★★★★☆
Overview: Krystal Biotech, Inc. is a commercial-stage biotechnology company focused on discovering, developing, manufacturing, and commercializing genetic medicines for diseases with high unmet medical needs in the United States, with a market cap of $4.13 billion.
Operations: The company's revenue segment primarily consists of $333.45 million from the business of developing and commercializing pharmaceuticals.
Insider Ownership: 10.6%
Earnings Growth Forecast: 32.7% p.a.
Krystal Biotech is experiencing strong growth, with earnings expected to increase 32.7% annually, outpacing the US market. The company recently achieved a significant milestone by dosing the first patient in its Phase 3 IOLITE trial for KB803, aimed at treating corneal abrasions in DEB patients. Despite lower profit margins this year compared to last, Krystal's revenue is projected to grow at 26.2% per year, significantly above market rates.
- Click here to discover the nuances of Krystal Biotech with our detailed analytical future growth report.
- The analysis detailed in our Krystal Biotech valuation report hints at an deflated share price compared to its estimated value.
Frontline (FRO)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Frontline plc is a shipping company that owns and operates oil and product tankers globally, with a market cap of $3.88 billion.
Operations: The company generates revenue of $1.90 billion from its tanker operations.
Insider Ownership: 35.8%
Earnings Growth Forecast: 26.8% p.a.
Frontline is trading significantly below its estimated fair value, presenting a good relative value compared to peers. Despite a recent decline in revenue and net income, the company is forecasted to achieve substantial earnings growth of 26.8% annually over the next three years, outpacing market expectations. However, revenue is expected to decline by 11.9% per year during this period. The dividend remains unstable following a decrease in the latest declaration.
- Dive into the specifics of Frontline here with our thorough growth forecast report.
- Upon reviewing our latest valuation report, Frontline's share price might be too pessimistic.
Next Steps
- Reveal the 195 hidden gems among our Fast Growing US Companies With High Insider Ownership screener with a single click here.
- Ready To Venture Into Other Investment Styles? The end of cancer? These 24 emerging AI stocks are developing tech that will allow early idenification of life changing disesaes like cancer and Alzheimer's.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
Valuation is complex, but we're here to simplify it.
Discover if Frontline might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com